Metraipolis › archive › dc_e178a1edee0f

Efficacy and safety of pembrolizumab for the treatment of advanced or recurrent ovarian cancer: a meta-analysis based on single-arm studies — Europe PMC PMID:41103419

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41103419
DOI
10.3389/fimmu.2025.1662455
License (as archived)
solo-consultazione
Archived
2026-11-09T15:03:21.797Z
SHA-256 of the archived text
ba6e97c3713326e3ec36a37e5bfe1108b8a30ca562b4b2f912ed35be014eabb0
Stable URL of this page
https://metraipolis.com/documento/dc_e178a1edee0f

How to cite

Efficacy and safety of pembrolizumab for the treatment of advanced or recurrent ovarian cancer: a meta-analysis based on single-arm studies — Europe PMC PMID:41103419 — Europe PMC (en), https://europepmc.org/article/MED/41103419 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e178a1edee0f (Metraipolis archive dc_e178a1edee0f, sha256 ba6e97c3713326e3ec36a37e5bfe1108b8a30ca562b4b2f912ed35be014eabb0)
BibTeX
@misc{dce178a1edee0f,
  title = {Efficacy and safety of pembrolizumab for the treatment of advanced or recurrent ovarian cancer: a meta-analysis based on single-arm studies — Europe PMC PMID:41103419},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41103419},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e178a1edee0f; sha256 ba6e97c3713326e3ec36a37e5bfe1108b8a30ca562b4b2f912ed35be014eabb0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41103419. Agents can read the archived copy with the MCP tool read_document.